Content Preview
Newsday/Optimum Online® subscribers click here for full access
Not a Newsday or Optimum Online® subscriber? Click here
Human Genome Sciences seeks approval for Zalbin
NEW YORK (AP) — Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
The Rockville, Md., company did not say when it expected a response to its biologics license application, which was submitted to the Food and Drug Administration. Human Genome Sciences said its partner Novartis AG will file for European Union approval before the end...
newsday.com is now available at no charge to Newsday and Optimum Online® subscribers. To continue reading, please log in or register now.
-
Already
registered on
newsday.com?
log in -
Already a subscriber
to Newsday or
Optimum Online®?
get access -
Not a Newsday
or Optimum Online®
subscriber?
click here
